Literature DB >> 23923350

Pro-inflammatory and anti-inflammatory cytokine response in diarrhoea-predominant irritable bowel syndrome patients.

S V Rana1, S Sharma, S K Sinha, K K Parsad, A Malik, K Singh.   

Abstract

BACKGROUND AND AIM: Irritable bowel syndrome (IBS) is referred to as a functional bowel disorder which is diagnosed by a number of characteristic symptoms (Rome II criteria) in the absence of detectable structural abnormalities. Low-grade inflammation of the intestine may be one of the reasons for development of diarrhoea-predominant IBS (IBS-D). We undertook this study to estimate the serum levels of pro-inflammatory (IL-6, TNF-alpha) and anti-inflammatory (IL-10) cytokines in IBS-D patients.
METHODS: A total of 108 diarrhoea patients were screened. Out of these only 63 adult IBS-D patients were enrolled. Age and sex matched 62 apparently healthy controls with no GI symptoms were also recruited. Out of 63 IBS-D patients, 37 were males while there were 32 males among the controls. The patients with IBS-D were diagnosed according to the Rome II criteria. Levels of serum IL-6, TNF-alpha and IL-10 were measured in all subjects using ELISA.
RESULTS: Mean (+/- SD) age of IBS-D patients (42.6 +/- 19.5 years) was comparable (p = 0.64) to that of controls (43.5 +/- 18.7 years). The mean (+/- SD) levels of IL-6 in IBS-D patients (32.2 +/- 12.01 pg/ml) was significantly higher (p < 0.001) than in controls (7.48 +/- 2.55 pg/ml). The levels of TNF-alpha in IBS-D patients (16.3 +/- 5.2 pg/ml) were also significantly higher (p < 0.05) than in controls (7.94 +/- 2.19 pg/ml). There was no significant difference in the serum levels of IL-10 (p = 0.23) between IBS-D patients (5.75 +/- 2.1 pg/ml) and controls (5.84 +/- 1.9 pg/ml).
CONCLUSION: Our results indicate that mild inflammation is involved in IBS-D patients as proinflammatory cytokines were increased although no difference in anti-inflammatory cytokine was observed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23923350     DOI: 10.7869/tg.2012.66

Source DB:  PubMed          Journal:  Trop Gastroenterol        ISSN: 0250-636X


  23 in total

1.  Global Cytokine Profiles and Association With Clinical Characteristics in Patients With Irritable Bowel Syndrome.

Authors:  Sean M P Bennet; Annikka Polster; Hans Törnblom; Stefan Isaksson; Sandrine Capronnier; Aurore Tessier; Boris Le Nevé; Magnus Simrén; Lena Öhman
Journal:  Am J Gastroenterol       Date:  2016-06-07       Impact factor: 10.864

2.  The CCL28 levels are elevated in the serum of patients with irritable bowel syndrome and associated with the clinical symptoms.

Authors:  Farshad Sheikhesmaili; Ali Jalili; Elmira Taghizadeh; Shohreh Fakhari; Khashaiar Jalili; Ebrahim Ghaderi; Ezatollah Rahimi
Journal:  Am J Clin Exp Immunol       Date:  2021-02-15

Review 3.  New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists.

Authors:  Amy E Foxx-Orenstein
Journal:  Therap Adv Gastroenterol       Date:  2016-02-21       Impact factor: 4.409

4.  Sustained stimulation of β2- and β3-adrenergic receptors leads to persistent functional pain and neuroinflammation.

Authors:  Xin Zhang; Jane E Hartung; Andrey V Bortsov; Seungtae Kim; Sandra C O'Buckley; Julia Kozlowski; Andrea G Nackley
Journal:  Brain Behav Immun       Date:  2018-06-20       Impact factor: 7.217

5.  Faecalibacterium prausnitzii prevents physiological damages in a chronic low-grade inflammation murine model.

Authors:  Rebeca Martín; Sylvie Miquel; Florian Chain; Jane M Natividad; Jennifer Jury; Jun Lu; Harry Sokol; Vassilia Theodorou; Premysl Bercik; Elena F Verdu; Philippe Langella; Luis G Bermúdez-Humarán
Journal:  BMC Microbiol       Date:  2015-03-21       Impact factor: 3.605

6.  Cytokine Levels and Symptoms Among Women with Irritable Bowel Syndrome: Considering the Role of Hormonal Contraceptive Use.

Authors:  Kendra J Kamp; Claire Han; Robert J Shulman; Kevin C Cain; Pamela Barney; Mark R Opp; Lin Chang; Robert L Burr; Margaret M Heitkemper
Journal:  Biol Res Nurs       Date:  2020-07-17       Impact factor: 2.522

7.  Risk of Psychiatric Disorders following Irritable Bowel Syndrome: A Nationwide Population-Based Cohort Study.

Authors:  Yao-Tung Lee; Li-Yu Hu; Cheng-Che Shen; Min-Wei Huang; Shih-Jen Tsai; Albert C Yang; Chang-Kuo Hu; Chin-Lin Perng; Yi-Shin Huang; Jeng-Hsiu Hung
Journal:  PLoS One       Date:  2015-07-29       Impact factor: 3.240

8.  The inhibitory effect of tongxieyaofang on rats with post infectious irritable bowel syndrome through regulating colonic par-2 receptor.

Authors:  Xuguang Hu; Xiaojun Zhang; Bin Han; Weijian Bei
Journal:  BMC Complement Altern Med       Date:  2013-10-02       Impact factor: 3.659

9.  Chemotactic chemokines are important in the pathogenesis of irritable bowel syndrome.

Authors:  Charles Darkoh; Latoya Comer; Getie Zewdie; Stephen Harold; Ned Snyder; Herbert L Dupont
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

10.  Novel insights which may translate into treatments for irritable bowel syndrome.

Authors:  Angelo A Izzo
Journal:  Front Pharmacol       Date:  2013-12-31       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.